Key Takeaways
- • Soufflé Therapeutics, a Watertown, Massachusetts biotech, raised $135 million in a Series B financing, according to the Boston Business Journal.
- • The company has accumulated more than $3.5 billion from capital raised and collaboration agreements since launching roughly one year earlier.
- • Serial entrepreneur Bob Langer is a co-founder of Soufflé Therapeutics, per publisher context.
Summary
Soufflé Therapeutics has raised $135 million in a Series B round, the Boston Business Journal reported on October 14, 2026. The Watertown-based biotech launched about a year before the raise and already holds more than $3.5 billion from capital raised and collaboration agreements, according to the report by reporter Hannah Baratham-Green.
The headline figure underscores the scale of backing the company has attracted in a short period. The combination of equity capital and collaboration agreements suggests that partnerships with larger pharmaceutical or biotech counterparts are a significant component of the company's funding base, though the primary source does not itemize the split between the two.
Publisher context identifies serial entrepreneur Bob Langer as a co-founder of the company. The primary article does not provide additional detail on the Series B investor syndicate, valuation, or the specific therapeutic programs the proceeds will fund.
The article sits within a broader Boston-area life sciences news cycle, which during the same period included reports of two local biotechs pursuing IPOs and a Boehringer Ingelheim venture fund opening a Cambridge office. These items are separate stories and are not part of the Soufflé financing.
The headline figure underscores the scale of backing the company has attracted in a short period. The combination of equity capital and collaboration agreements suggests that partnerships with larger pharmaceutical or biotech counterparts are a significant component of the company's funding base, though the primary source does not itemize the split between the two.
Publisher context identifies serial entrepreneur Bob Langer as a co-founder of the company. The primary article does not provide additional detail on the Series B investor syndicate, valuation, or the specific therapeutic programs the proceeds will fund.
The article sits within a broader Boston-area life sciences news cycle, which during the same period included reports of two local biotechs pursuing IPOs and a Boehringer Ingelheim venture fund opening a Cambridge office. These items are separate stories and are not part of the Soufflé financing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.